Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 10 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/30/2007 First Published: 3/1/2001


1.		Phase III Randomized Study of Nolatrexed Dihydrochloride Versus Doxorubicin in Patients With Unresectable or Recurrent Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				ZARIX-ZX101-301 AG-337-301, NCT00012324

Last Modified: 9/1/1995


2.		Phase II Study of Continuous-Infusion AG-337 (a Thymidylate Synthase Inhibitor) for Adenocarcinoma of the Pancreas (Summary Last Modified 09/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				over 18				Pharmaceutical / Industry				AG-337-006 NCI-V95-0632

Last Modified: 8/1/1995


3.		Phase II Study of AG337 (a Thymidylate Synthase Inhibitor) as a 5-Day Continuous Infusion for Primary Hepatocellular Carcinoma (Summary Last Modified 08/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				AG-337-008 NCI-V95-0633

Last Modified: 6/1/1997


4.		Phase II Study of AG337 (a Thymidylate Synthase Inhibitor) as a 5-Day Continuous Infusion for Prostate Cancer (Summary Last Modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				AG-337-007 NCI-V95-0634

Last Modified: 1/1/1996


5.		Phase II Study of AG337 by 5-Day Continuous Infusion in Adenocarcinoma of the Colon (Summary Last Modified 01/96)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over								AG-337-009 NCI-V95-0635

Last Modified: 8/1/1995


6.		Phase II Study of AG-337 (a Thymidylate Synthase Inhibitor) as a 5-Day Continuous Infusion for Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 08/95)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				AG-337-004 NCI-V95-0636

Last Modified: 6/1/1997


7.		Phase II Study of AG337 (a Thymidylate Synthase Inhibitor) as a 5-Day Continuous Infusion for Stage IIIB/IV Nonsmall Cell Lung Cancer (Summary Last Modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				AG-337-005 NCI-V95-0637

Last Modified: 2/1/1998


8.		Phase II Study of AG337 (a Thymidylate Synthase Inhibitor) Administered as a 5-Day Continuous Infusion for Locally Advanced or Metastatic Hepatocellular Carcinoma (Summary Last Modified 02/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				AG-337-015 NCI-V96-0946

Last Modified: 2/1/1998


9.		Phase II Randomized Study of AG337 (a Thymidylate Synthase Inhibitor) vs MTX in Patients Who Have Failed First-Line Chemotherapy for Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 02/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				AG-337-016 NCI-V96-0949

Last Modified: 2/1/1998


10.		Phase I Study of Continuous-Infusion AG337, a Thymidylate Synthase Inhibitor, plus CDDP for Advanced Solid Tumors (Summary Last Modified 02/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				AG-337-013 NCI-V96-0874

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute